US-based Bridgefield Capital will acquire the Philips Emergency Care business and resuscitation products.


RT’s Three Key Takeaways

  1. Philips Sells Emergency Care Business: Philips has agreed to sell its Emergency Care division, including AEDs and defibrillators, to U.S.-based investment firm Bridgefield Capital.
  2. Brand Licensing Agreement: Philips will allow the Emergency Care business to use its brand for up to 15 years under an exclusive license for manufacturing, sales, and marketing.
  3. Strategic Focus Shift: The sale aligns with Philips’ strategy to concentrate on areas with greater scale and financial impact, with the transaction expected to close in the second half of 2025 pending regulatory approval.

Royal Philips has signed an agreement to sell its Emergency Care business — which includes AEDs, advanced life support defibrillators, and prehospital monitoring solutions — to Bridgefield Capital, a US-based investment firm.

Philips and the Emergency Care business will enter into an exclusive brand license agreement to use the Philips brand for manufacturing, sales, and marketing of Emergency Care products globally for a period of up to 15 years.

The Emergency Care business, which is part of the Connected Care segment, offers products that play a critical role in acute care management, both inside and outside the hospital, including cardiac resuscitation, such as automated external defibrillators, and emergency care devices for professional and consumer applications.

As part of Philips’ renewed company strategy, as presented in January, 2023, the company is concentrating its resources where it can achieve larger scale and financial impact. Against this background, Philips carefully considered options for its Emergency Care business, and decided to divest this business to Bridgefield Capital, a US-based investment firm that advises and invests in businesses to accelerate growth and profitability.

The transaction is subject to the satisfaction of certain closing conditions and receipt of regulatory approval, and is expected to be completed in the second half of 2025. Financial terms are not disclosed.